PDCD1 and colorectal carcinoma: Two immune checkpoint inhibitors (ICIs), pembrolizumab and nivolumab, which are antibodies blocking programmed cell death-1 (PD-1), received regulatory approval in 2017 for the treatment of metastatic CRC that is mismatch-repair-deficient or has high levels of microsatellite instability [80].